CTRI/2021/09/036254
Not yet recruiting
未知
Incidence of adverse outcomes and risk factors for mortality among Mucormycosis patients in India: a multi-centric ambispective cohort study, 2021-2022
Dr Manickam P0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Dr Manickam P
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Mucormycosis patients admitted between 1st March 2021 and 31st July 2021
- •\- Hospitalised for Mucormycosis in the study hospital
Exclusion Criteria
- •\- Mucormycosis patients who could not be contacted despite two phone calls
- •\- Not available for follow\-up during the study period
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Prevalence, Risk Factors and Clinical Outcomes of Sepsis Induced Myocardial Dysfunction (SIMD): A Prospective Study in King Chulalongkorn Memorial Hospital, ThailandSepsis induced myocardial dysfunctionSepsis induced myocardial dysfunction, septic shock, sepsis, echocardiogramTCTR20221112004Faculty of Medicine, Chulalongkorn university72
Active, not recruiting
Not Applicable
The study of possible risk factors associated with mild cognitive impairment in patients with the Metabolic SyndromeMetabolic syndromeMetabolic syndrome ,Mild Cognitive Impairment (MCI),Peripheral Markers,Neutrophil-Lymphocyte ratioTCTR20171004002Faculty of Medicine, Chiang Mai University300
Recruiting
Not Applicable
Pain Assessment in patients undergoing neurosurgeryHealth Condition 1: G891- Acute pain, not elsewhere classifiedHealth Condition 2: G892- Chronic pain, not elsewhere classifiedCTRI/2021/09/036525IMHANS
Completed
Not Applicable
To know the outcome of specially prepared blood derivative on treatment of decay of bone due to certain cancer medicines commonly termed as MRONJ (Medicine related osteonecrosis of jaw)Health Condition 1: null- malignant disease and bony metastases receiving antiresorptives namely Zolendronate, Clorandonate, Palmidronate, Ebandronate and DenosumabCTRI/2017/09/009615no269
Completed
Not Applicable
Incidence, Outcome and Risk Factors for Mortality of Upper Gastrointestinal Hemorrhage Patients-Incidence of Upper Gastrointestinal Hemorrhage-Outcome of treatment -Risk Factors for Mortality of Upper Gastrointestinal Hemorrhage Patients in THAI SICU StudyUpper gastrointestinal hemorrhage,Critical care,Mortality,Risk factorsTCTR20150720001Medical Research Network-MedResNet4,654